Alvotech 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- For the first 9 months of 2026, Alvotech reported total revenue of $323 million, down 23% year over year, and adjusted EBITDA of $78 million, up 15% year over year, with a 24% margin.
- Q3 total revenue was $112 million, up 5% from Q2 and down 2% year over year; product revenue was $58 million, up 78% year over year and 6% quarter on quarter.
- Q3 gross margin was 54%, up 3 percentage points from Q2, and adjusted EBITDA was $31 million, up 40% quarter on quarter and double the same period last year.
- First-9-month product revenue was $164 million and licensing revenue was $159 million; Alvotech had 5 in-market products generating product revenue.
- Cash on hand at quarter-end was €61 million, compared with €143 million at the beginning of the quarter; cash used in operations was €89 million, including a €116 million working-capital outflow.
- Alvotech received two FDA approvals in October for Simlandi at its Reykjavík facility: additional U.S. manufacturing capacity across DSM 1 and DSM 2, and the enhanced Process 2.0 manufacturing process.
- Process 2.0 more than doubles drug-substance output per batch at the same upstream manufacturing scale, and Alvotech said it was supplying product made using the process to U.S. and European markets for Q4 2026.
- Simlandi remained the number 2 adalimumab biosimilar in the U.S.; Hukindra continued to show sustained demand in Europe, while Solaristi and Uspuvo benefited from biosimilar adoption and market access.
- AVT-05 was present in 13 European markets, including all 5 major markets; AVT-06 had a footprint in more than 10 European markets and Japan.
- AVT-16 and AVT-80, proposed biosimilars to Entyvio, were under review in the U.S. and Europe, covering intravenous and subcutaneous presentations; AVT-29 became the first known worldwide regulatory submission for a proposed biosimilar to Eylea 8 mg.
- Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical for AVT-34 and AVT-87, proposed biosimilars to Mfinzi and Hemlibra, with potential upfront and milestone payments of up to approximately $150 million and future commercial supply revenue.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Alvotech Q3 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star, one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star, one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Benedikt Stefánsson, VP of Investor Relations and Global Communication.
Please go ahead. Thank you, and welcome to our listeners.
Yesterday evening, the company issued a press release announcing our financial results for the first nine months of 2026. Material accompanying today's earnings call, including the presentation we will be referring to on today's call, are available on our website, alvotech.com, in the Financial section. Our press release, presentations, and statements that we make on the call today may include forward-looking statements. These statements do not ensure future performance and are subject to risks and uncertainties that are outlined in company filings with the Securities and Exchange Commission. Any risks and uncertainties could cause actual results to differ materially from forward-looking statements that are made. Presenting on today's call are Róbert Wessman, founder and Executive Chairman, Lisa Graver, Chief Executive Officer, Joseph McClellan, Chief Operating Officer, and Linda Jónsdóttir, Chief Financial Officer. Róbert will begin today's presentation with a brief overview.
Lisa will then present a commercial and operations update, Joseph will provide a pipeline and regulatory update, and Linda will conclude with a discussion of the financial results. Following the presentation, our team will be happy to take your questions. With that, I would like to turn the call over to Róbert Wessman.
Good afternoon, everyone, and thank you for joining us here today. It is now just over two years since we entered the U.S. market commercially, and we have come a long way in that time. Today, we have a growing portfolio of commercial products across major global markets, and some of the most important opportunities in our history are directly ahead of us. We are expecting FDA approvals on three products before end of this year, including AVT05, which we believe has particularly strong potential. Beyond those near-term opportunities, we have built what we believe is one of the strongest biosimilar pipelines in the industry. Our programs for Entyvio and high-dose Eylea are great examples. We are among the first to file with Entyvio in both U.S. and Europe. With the high-dose Eylea, we made the first known regulatory filing anywhere in the world.
These are very large markets, and we believe being early puts Alvotech in a very strong position. We have also built the infrastructure to support that growth. We have invested more than half a billion dollars in our manufacturing capabilities in Iceland, created a world-class platform at the heart of Alvotech. While Iceland remains our home base, we are building an increasingly global and cost-effective supply chain through strategic partnership with Fujifilm, Lotte Biologics, and other long-term partners. Our business model is evolving too. Our new partnership with Lotus gives us, for the first time, the opportunity to commercialize two of our pipeline products directly in the U.S. market alongside our partner. We continue to lead the development and production and supply. At the same time, we are capturing more of the value chain. I believe Alvotech is now at a very important inflection point.
Today, we have one of the strongest pipelines in the industry. We have the manufacturing capabilities and the commercial reach to support the next phase of our growth. I am very excited about what lies ahead of Alvotech. We expect the fourth quarter to be the strongest in Alvotech history, and we have a strong order book as we move into the year 2027. With that, I will hand you over to Lisa to take you through the business updates.
Thank you, Róbert. I want to begin with two important FDA approvals we received in October for Simlandi at our Reykjavik facility. The approvals of additional manufacturing capacity and of our enhanced manufacturing process in DSM2 are significant developments. They follow the FDA's closure of its May inspection with a Voluntary Action Indicated classification and provide further evidence of the progress we have made in strengthening our manufacturing and quality systems. They also give us greater operational flexibility as we work to supply an expanding commercial portfolio. Joe will explain the technical implications and implementation in more detail. At our half-year results, we described a business with strong underlying demand but constrained product availability due to the cumulative impacts of the manufacturing slowdown related to our quality improvement programs. We explained that restoring production was the starting point and that the cadence in commercial deliveries would build over time.
The third quarter shows further progress along that path. Our focus remains on continuing to fulfill market demand and sustaining that progress through the important final quarter of the year. Turning briefly to our financial performance, revenue for the first nine months was $323 million, with EBITDA of $78 million, an increase of 15% year-over-year. As previously indicated, we expect a significant proportion of our full-year revenue and EBITDA to be generated in the fourth quarter. We now expect performance to trend towards the lower end of our stated range. Linda will walk you through the financial results in more details. Turning to our commercial and operating progress, I would highlight three drivers of value creation. First, commercial performance. Product and service revenue increased to $58 million in Q3, up 78% year-on-year, and 6% over the second quarter.
This is clear evidence of the gradual recovery we outlined in August. Our established products continue to demonstrate solid commercial traction, while newer launches are broadening the portfolio's geographic reach. Second, our pipeline, where we have continued to achieve important regulatory milestones. Our Entyvio biosimilar is now under review in both the U.S. and Europe, covering both intravenous and subcutaneous presentations. In Europe, AVT29 became the first known regulatory submission worldwide for a biosimilar to high-dose Eylea. Together, these programs position us to participate in the first wave of biosimilar competition in two important markets. The agreement with Lotus Pharmaceutical, announced by our partner after half-year results, is an important illustration of the commercial potential of our pipeline.
It gives Alvotech an opportunity to participate directly in the U.S. commercialization of biosimilars to Hemlibra and Imfinzi, alongside our partner, evolving our traditional partnership model and creating the potential to capture more value from these assets. Third, manufacturing, where our priority is to put our strengthened capabilities to work in support of reliable commercial supply. Reykjavik remains an important part of our manufacturing capacity, complemented over time by additional sourcing options through Lotte Biologics and Fujifilm. Taken together, these developments strengthen our ability to meet market demand consistently while building the portfolio and capabilities required for future growth. Turning to our established franchises, AVT02 and AVT04 continue to provide a strong commercial base for the business. In the U.S., Simlandi remains the number 2 adalimumab biosimilar, with market demand continuing to grow.
The recent FDA approvals provide additional manufacturing capacity and flexibility, which will help us address that demand as supply increases. In Europe, HUKYNDRA continues to demonstrate the longevity of the franchise, with sustained demand across key markets several years after launch. For AVT04, we are seeing relatively rapid biosimilar adoption. SELARSDI is benefiting from the expanding U.S. market as Teva builds formulary access, while UZPRUVO remains well-positioned in Europe as biosimilar conversion continues. Together, AVT02 and AVT04 provide an established commercial base as the contribution from our newer launches begins to broaden. With respect to our newer launches, we are particularly encouraged by the progress of AVT05, our biosimilar to Simponi. Together with Advanz Pharma, we have established a commercial presence in 13 European markets, including all five major markets. We are seeing encouraging momentum in Germany, Spain, the U.K., and France, supported by tender successes and expanding market access.
As the only golimumab biosimilar on the market in Europe, AVT05 benefits from a strong first-mover advantage. In the U.S., we continue to prepare for commercial launch with our partner, subject to the necessary regulatory approval and favorable resolution of a pending patent motion filed by the brand. A hearing was recently held in the Eastern District of Virginia following a motion for a preliminary injunction filed by the brand in an attempt to prevent our launch. While the court is expected to rule on the motion in the coming weeks, we remain confident in our position and that the motion will be denied. AVT06, our aflibercept two milligram biosimilar, has established a footprint across more than 10 European markets and in Japan. The broader aflibercept market is moving rapidly toward high-dose treatment, reinforcing the importance of AVT29 as a potential first-wave high-dose aflibercept biosimilar.
Beyond the progress of our marketed portfolio, we also took an important step in the evolution of our commercial strategy. As noted earlier, we announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical, covering AVT34 and AVT87, our proposed biosimilars to Imfinzi and Hemlibra. This agreement is particularly significant because, for the first time, Alvotech will have the opportunity to participate directly in the commercialization of its products in the U.S. Under the agreement, Lotus will commercialize both products through Alvogen, while Alvotech also retains the right to commercialize them directly. This represents an evolution of our established business model. Our global partner network remains central to our strategy, but where economics support it, we now have the option to participate more directly in commercialization and capture a greater share of the value we create through our integrated development and manufacturing platform.
At the same time, the agreement extends our commercial reach into eight Asian markets where Lotus will have exclusive commercialization rights. The agreement also provides for potential upfront and milestone payments of up to approximately $150 million, alongside future commercial supply revenue. We see this as an important example of how we can continue to evolve our partnership strategy, combining the strength of our established global network with more direct commercial participation where the opportunity and economics support it. More broadly, we continue to see interest in our development and manufacturing platform from potential partners. We are pursuing opportunities selectively, seeking terms that meet our partners' needs and create attractive value for Alvotech. With that, I will turn it to Joe to discuss our regulatory and manufacturing achievements in more detail and the continued progress of our development pipeline.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
